TY - JOUR
T1 - Assessing the Pathophysiology of Hyperglycemia in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study
T2 - From the Type 1 Diabetes in Acute Pancreatitis Consortium
AU - Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)
AU - Dungan, Kathleen M.
AU - Hart, Phil A.
AU - Andersen, Dana K.
AU - Basina, Marina
AU - Chinchilli, Vernon M.
AU - Danielson, Kirstie K.
AU - Evans-Molina, Carmella
AU - Goodarzi, Mark O.
AU - Greenbaum, Carla J.
AU - Kalyani, Rita R.
AU - Laughlin, Maren R.
AU - Pichardo-Lowden, Ariana
AU - Pratley, Richard E.
AU - Serrano, Jose
AU - Sims, Emily K.
AU - Speake, Cate
AU - Yadav, Dhiraj
AU - Bellin, Melena D.
AU - Toledo, Frederico G.S.
N1 - Funding Information:
K.M.D. has declared research support from Sanofi, Viacyte, Abbott, and Dexcom; consulting activities with Eli Lilly, Boehringer Ingelheim, Elsevier, and Dexcom; and honoraria from UptoDate, Medscape, Academy for Continued Healthcare Learning, and Cardiometabolic Health Congress. M.D.B. has declared research support from Viacyte and Dexcom and consulting activities with Insulet (advisory board). C.E.-M. has received research support from Lilly, Astellas Pharma, Bristol Myers Squibb, and Nimbus Therapeutics and consulting/advisory fees from Avotres, Inc, DiogenX, Isla Technologies, Provention Bio, Inc, MaiCell Therapeutics, and Dompe. R.E.P. has received grants (directed to his institution) from Hanmi Pharmaceutical Co, Ltd, Janssen, Metavention, Novo Nordisk, Poxel SA, and Sanofi; has received consulting fees (directed to his institution) from AstraZeneca, Corcept Therapeutics Incorporated, Glytec LLC, Hanmi Pharmaceutical Co, Ltd, Janssen, Merck & Co, Inc., Mundipharma, Novo Nordisk, Pfizer, Inc, Sanofi, Scohia Pharma, Inc, and Sun Pharmaceutical Industries; and has received support for attending meetings/travel (directed to his institution or to the travel provider) from AstraZeneca, Glytec LLC, Merck & Co, Inc, Mundipharma, Novo Nordisk, and Pfizer, Inc. E.K.S. has received honoraria from Medscape. C.S. has participated on an advisory board for Vertex Pharmaceuticals. F.G.S.T. has declared research support from Dompé Pharmaceuticals and previous consulting activities with Sanofi, Eli Lilly, and AstraZeneca. The other authors declare no conflict of interest.
Funding Information:
The T1DAP Consortium is funded by the National Institute of Diabetes and Digestive and Kidney Diseases: grants U01DK127384, U01DK127367, U01DK127377, U01DK127392, U01DK127382, U01DK127403, U01DK127404, U01DK127388, U01DK127395, U01DK127378, and U01DK127400. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Objectives The metabolic abnormalities that lead to diabetes mellitus (DM) after an episode of acute pancreatitis (AP) have not been extensively studied. This article describes the objectives, hypotheses, and methods of mechanistic studies of glucose metabolism that comprise secondary outcomes of the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) Study. Methods Three months after an index episode of AP, participants without preexisting DM will undergo baseline testing with an oral glucose tolerance test. Participants will be followed longitudinally in three subcohorts with distinct metabolic tests. In the first and largest subcohort, oral glucose tolerance tests will be repeated 12 months after AP and annually to assess changes in β-cell function, insulin secretion, and insulin sensitivity. In the second, mixed meal tolerance tests will be performed at 3 and 12 months, then annually, and following incident DM to assess incretin and pancreatic polypeptide responses. In the third, frequently sampled intravenous glucose tolerance tests will be performed at 3 months and 12 months to assess the first-phase insulin response and more precisely measure β-cell function and insulin sensitivity. Conclusions The DREAM study will comprehensively assess the metabolic and endocrine changes that precede and lead to the development of DM after AP.
AB - Objectives The metabolic abnormalities that lead to diabetes mellitus (DM) after an episode of acute pancreatitis (AP) have not been extensively studied. This article describes the objectives, hypotheses, and methods of mechanistic studies of glucose metabolism that comprise secondary outcomes of the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) Study. Methods Three months after an index episode of AP, participants without preexisting DM will undergo baseline testing with an oral glucose tolerance test. Participants will be followed longitudinally in three subcohorts with distinct metabolic tests. In the first and largest subcohort, oral glucose tolerance tests will be repeated 12 months after AP and annually to assess changes in β-cell function, insulin secretion, and insulin sensitivity. In the second, mixed meal tolerance tests will be performed at 3 and 12 months, then annually, and following incident DM to assess incretin and pancreatic polypeptide responses. In the third, frequently sampled intravenous glucose tolerance tests will be performed at 3 months and 12 months to assess the first-phase insulin response and more precisely measure β-cell function and insulin sensitivity. Conclusions The DREAM study will comprehensively assess the metabolic and endocrine changes that precede and lead to the development of DM after AP.
KW - AIRg - acute insulin response to glucose
KW - AP - acute pancreatitis
KW - AUC - area under the curve
KW - DM - diabetes mellitus
KW - DREAM - Diabetes Related to Acute Pancreatitis and its Mechanisms
KW - FSIGTT - frequently sampled intravenous glucose tolerance test
KW - GIP - glucose-dependent insulinotropic polypeptide
KW - GLP-1 - glucagon-like peptide 1
KW - HOMA-IR - homeostasis model assessment-insulin resistance
KW - MMTT - mixed meal tolerance test
KW - OGTT - oral glucose tolerance test
KW - PP - pancreatic polypeptide
KW - frequently sampled intravenous glucose tolerance test
KW - islet
KW - mixed-meal tolerance test
KW - pancreatogenic diabetes
KW - type 3c diabetes mellitus
KW - β-cell function
UR - http://www.scopus.com/inward/record.url?scp=85139571728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139571728&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000002074
DO - 10.1097/MPA.0000000000002074
M3 - Article
C2 - 36206461
AN - SCOPUS:85139571728
SN - 0885-3177
VL - 51
SP - 575
EP - 579
JO - Pancreas
JF - Pancreas
IS - 6
ER -